Hylly SA-Intellectual property quarterly
Henkilönnimi Owade, Victor, kirjoittaja.
Nimeke- ja vastuullisuusmerkintö TRIPS and COVID-19 : Is an IP waiver (Un)necessary?
Julkaistu
Ulkoasutiedot
Sarjamerkintö ei-lisäkirjausmuodossa Intellectual Property Quarterly, ISSN 1364-906X ; 1/2022
Huomautus sisällöstä, tiivistelmä tms. This article critically examines whether a waiver of intellectual property rights and obligations in the WTO during the COVID-19 pandemic is a necessary legal remedy to address public concerns about accessing, manufacturing, and distributing vaccines and related technologies. It concludes that a waiver is not necessary since all states can carefully adapt their national intellectual property laws to specifically address COVID-19 vaccine supply challenges and based on available evidence, the protection and enforcement of intellectual property rights seem not to be problematic with regard to fair and equitable access and the global manufacturing and distribution of vaccines. So rather than a waiver, clarifying the use of flexibilities during the circumstances of a pandemic is a better way forward for addressing future vaccine challenges given the pivotal role of intellectual property rights in spurring medical innovation and voluntary public interest licensing and knowledge transfer.
Asiasana
*000 ab a ar
*00116529
*008 s2022||||xxk|||||||||||||||||eng||
*041 $aeng
*1001 $aOwade, Victor,$ekirjoittaja.
*24510$aTRIPS and COVID-19 :$bIs an IP waiver (Un)necessary? /$cVictor Owade.
*260 $c2022
*300 $as. 30-43
*4900 $aIntellectual Property Quarterly,$x1364-906X ;$v1/2022
*520 $aThis article critically examines whether a waiver of intellectual property rights and obligations in the WTO during the COVID-19 pandemic is a necessary legal remedy to address public concerns about accessing, manufacturing, and distributing vaccines and related technologies. It concludes that a waiver is not necessary since all states can carefully adapt their national intellectual property laws to specifically address COVID-19 vaccine supply challenges and based on available evidence, the protection and enforcement of intellectual property rights seem not to be problematic with regard to fair and equitable access and the global manufacturing and distribution of vaccines. So rather than a waiver, clarifying the use of flexibilities during the circumstances of a pandemic is a better way forward for addressing future vaccine challenges given the pivotal role of intellectual property rights in spurring medical innovation and voluntary public interest licensing and knowledge transfer.
*650 7$aCOVID-19$2yso/fin$0http://www.yso.fi/onto/yso/p38829
*650 7$apatentit$0http://www.yso.fi/onto/yso/p3069$2yso/fin
*650 7$aimmateriaalioikeus$0http://www.yso.fi/onto/yso/p3068$2yso/fin
*650 7$avastuuvapaus $0http://www.yso.fi/onto/yso/p24518$2yso/fin
*852 $hSA-Intellectual property quarterly
^
Tästä teoksesta ei ole arvioita.
Näpäytä
kun haluat kirjoittaa ensimmäisen arvion.